Interviews

A Look at Longevity Industry: Interview with Dr. Eric Leire, CEO of Genflow Biosciences

by Andrii Buvailo, PhD  (contributor )   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

The aging research industry has exploded in recent years. Once a fringe area of science, aging research has now gained widespread recognition for its potential to address the challenges of an aging population and extend a healthy lifespan. This growth is due, in part, to the increasing costs of caring for an aging population and the recognition of the importance of understanding the biological processes of aging. Today, researchers, biotech companies, and pharmaceutical firms are all working to develop interventions that could delay or even reverse the aging process.

In this interview, I asked Dr. Eric Leire several questions about aging research and the longevity industry. Dr. Eric Leire is CEO of Genflow Biosciences, a publicly traded UK-based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA. The team at Genflow Biosciences is developing therapeutics that can potentially halt or slow the aging process in humans and dogs. The company's research focuses on a centenarian variant of the SIRT6 gene. 

#advertisement
AI in Drug Discovery Report 2025

Continue reading

This content available exclusively for BPT Mebmers

Topics: Aging & Longevity   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email